onc Videos

Videos

Videos

Treatment Landscape for Patients With Metastatic NSCLC Without Actionable Mutations

10/05/2023

At the Great Debates & Updates in Lung Cancer Meeting in New York, Karen Reckamp, MD, gave an overview of the treatment landscape for patients with metastatic non-small cell lung cancers that do not have actionable mutations.

At the Great Debates & Updates...

10/05/2023

Oncology

Videos

The Case for Neoadjuvant Immunotherapy in Resectable NSCLC

10/05/2023

Jamie Chaft , MD;

At the Great Debates & Updates meeting in New York, Jamie Chaft, MD, debated in favor of neoadjuvant immunotherapy in resectable non-small cell lung cancer.

At the Great Debates & Updates...

10/05/2023

Oncology

Nataliya Uboha, MD, Carbone Cancer Center

Videos

Utilizing Biomarkers to Optimize Treatment for Upper Gastrointestinal Cancers

09/29/2023

Nataliya Uboha , MD, PhD;

At the Great Debates & Updates in Gastrointestinal Malignancies meeting, Nataliya Uboha, MD, PhD, discusses the use of biomakers to choose the best treatment for patients with upper GI cancers.

At the Great Debates & Updates...

09/29/2023

Oncology

Videos

The Case for Immunotherapy Alone for Patients With PD-L1-High NSCLC in the First-Line Setting

09/29/2023

Jamie Chaft , MD;

At the Great Debates & Updates meeting in New York, Jamie Chaft, MD, debated in favor of using immunotherapy alone in the first-line setting for patients with high PD-L1 expression and non-small cell lung cancer.

At the Great Debates & Updates...

09/29/2023

Oncology

Videos

The Case for Lorlatinib in ALK-Positive NSCLC

09/28/2023

Misako Nagasaka , MD, PhD;

At the Great Debates & Updates in Lung Cancer meeting, Misako Nagasaka, MD, PhD, debated in favor of lorlatinib over alectinib when considering treatment options for patients with ALK-positive non-small cell lung cancer (NSCLC).

At the Great Debates & Updates...

09/28/2023

Oncology

Videos

How to Handle Elderly Patients and Those With Performance Status 2 NSCLC

09/28/2023

Corey J. Langer , MD, FACP;

At the Great Debates & Updates in Lung Cancer meeting Corey Langer, MD, discussed the therapeutic landscape for underserved patients with non-small cell lung cancer — elderly patients, and patients with ECOG performance status 2.

At the Great Debates & Updates...

09/28/2023

Oncology

Videos

The Role of Circulating Tumor DNA in Colorectal Cancer

09/28/2023

Aparna Parikh , MD;

At the Great Debates & Updates in Gastrointestinal Malignancies meeting, Aparna Parikh, MD, presented on the role circulating tumor DNA may have in the treatment of patients with colorectal cancer.

At the Great Debates & Updates...

09/28/2023

Oncology

Videos

The Case for Adjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer

09/26/2023

Patrick Forde , MD;

At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Patrick Forde, MD, debated in favor of adjuvant immunotherapy in resectable non-small cell lung cancer.

At the Great Debates & Updates...

09/26/2023

Oncology

Videos

The Case for Chemoimmunotherapy for Patients With PD-L1-High Non-Small Cell Lung Cancer in the First-Line Setting

09/26/2023

Patrick Forde , MD;

At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Patrick Forde, MD, Johns Hopkins, debated in favor of chemoimmunotherapy in PD-L1 high non-small cell lung cancer.

At the Great Debates & Updates...

09/26/2023

Oncology

Videos

Novel Checkpoint Inhibitor Combinations for Lung Cancer

09/26/2023

Hossein Borghaei , DO, MS;

At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Hossein Borghaei, DO, MS, discussed the development of novel combinations of checkpoint inhibitors to better treat patients with refractory lung cancers.

At the Great Debates & Updates...

09/26/2023

Oncology

Recent News

News

FDA Grants Approval to Revumenib for Patients With R/R Acute Leukemia With KMT2A Translocation

11/17/2024

On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.

On November 15, 2024, the FDA...

11/17/2024

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology